Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma

Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fak&uuml;ltesi, &Ccedil;agis Kamp&uuml;s&uuml;, Balikesir, TurkeyAbstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients&#39; qualit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Ermiş&nbsp;SS
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e52a282039324e1a80029e0184504467
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e52a282039324e1a80029e0184504467
record_format	dspace
spelling	oai:doaj.org-article:e52a282039324e1a80029e01845044672021-12-02T06:10:54ZDifferential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma1177-54671177-5483https://doaj.org/article/e52a282039324e1a80029e01845044672012-05-01T00:00:00Zhttp://www.dovepress.com/differential-pharmacology-and-clinical-utility-of-preservative-free-ta-a9840https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fak&uuml;ltesi, &Ccedil;agis Kamp&uuml;s&uuml;, Balikesir, TurkeyAbstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients&#39; quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F2&alpha;, clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies.Keywords: tafluprost, AFP 168, glaucoma, intraocular pressure, preservativeErmiş&nbsp;SSDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2012, Iss default, Pp 673-678 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Ermiş&nbsp;SS Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
description	Sitki Samet ErmişFaculty of Medicine, Balikesir University, Tip Fak&uuml;ltesi, &Ccedil;agis Kamp&uuml;s&uuml;, Balikesir, TurkeyAbstract: Glaucoma is a chronic disease requiring lifelong treatment. Discomfort due to medications may affect patients&#39; quality of life and may cause poor compliance, which leads to poor intraocular pressure control. To minimize the side effects of long-term treatment, preparations with lower benzalkonium chloride concentrations, preservative-free preparations and alternative preservatives have been developed and reported to have a lower rate of side effects. Tafluprost, launched on the ophthalmic market in 2008, is a new 16-phenoxy analogue of prostaglandin F2&alpha;, clinically used as an ocular hypotensive agent for the treatment of glaucoma and ocular hypertension. The safety and intraocular pressure-lowering efficacy of tafluprost has been demonstrated in various preclinical and clinical studies.Keywords: tafluprost, AFP 168, glaucoma, intraocular pressure, preservative
format	article
author	Ermiş&nbsp;SS
author_facet	Ermiş&nbsp;SS
author_sort	Ermiş&nbsp;SS
title	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
title_short	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
title_full	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
title_fullStr	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
title_full_unstemmed	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
title_sort	differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/e52a282039324e1a80029e0184504467
work_keys_str_mv	AT ermisampnbspss differentialpharmacologyandclinicalutilityofpreservativefreetafluprostinthetreatmentofocularhypertensionandglaucoma
_version_	1718400082813911040

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma

Ejemplares similares